Guy A. Young

Hematology | Oncology

4650 W Sunset Blvd
Los Angeles, CA 90027

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 178 publications

Advances in Hemophilia: New Treatments and Complications in Laboratory Testing/Monitoring.

Advances in Hemophilia: New Treatments and Complications in Laboratory Testing/Monitoring.

Journal: Clinics in laboratory medicine

Published: May 15, 2026

Safety and efficacy of fondaparinux in pediatric venous thromboembolism: A retrospective cohort study.

Safety and efficacy of fondaparinux in pediatric venous thromboembolism: A retrospective cohort study.

Journal: Thrombosis research

Published: May 11, 2026

Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents.

Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents.

Journal: American journal of hematology

Published: May 06, 2026

From nothing to abundance for hemophilia with inhibitors.

From nothing to abundance for hemophilia with inhibitors.

Journal: Blood

Published: February 26, 2026

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.

Journal: Blood advances

Published: January 30, 2026

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Journal: Blood advances

Published: January 30, 2026

T2* Magnetic Resonance Imaging Uncovers Hemosiderin Burden in Pediatric Hemophilia: A Call for Sensitive Imaging Biomarkers.

T2* Magnetic Resonance Imaging Uncovers Hemosiderin Burden in Pediatric Hemophilia: A Call for Sensitive Imaging Biomarkers.

Journal: Pediatric blood & cancer

Published: January 02, 2026

Denecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors - 26-week results from FRONTIER.

Denecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors - 26-week results from FRONTIER.

Journal: Blood advances

Published: December 19, 2025

Deconstructing gene therapy in hemophilia for the clinician.

Deconstructing gene therapy in hemophilia for the clinician.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half-Life FVIII versus Non-FVIII Therapies.

Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half-Life FVIII versus Non-FVIII Therapies.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: October 09, 2025

Emicizumab in infants: not just cost-effective but mandatory.

Emicizumab in infants: not just cost-effective but mandatory.

Journal: Blood advances

Published: August 12, 2025

The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.

The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.

Journal: Journal of thrombosis and haemostasis : JTH

Published: June 10, 2025

Showing 1-12 of 178

Last Updated: 09/26/2026